Literature DB >> 18586692

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Somaia Mohamed1, Robert Rosenheck, Joseph McEvoy, Marvin Swartz, Scott Stroup, Jeffrey A Lieberman.   

Abstract

BACKGROUND: We evaluated the cross-sectional and longitudinal association of measures of both insight and attitudes toward medication to outcomes that included psychopathology and community functioning.
METHODS: Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) was a large 18-month follow-up study pharmacotherapy of people with schizophrenia. Insight was measured using the Insight and Treatment Attitudes Questionnaire and attitudes toward medication by the Drug Attitude Inventory. Widely known scales were used to assess symptoms of schizophrenia and depression and community functioning. Medication adherence was globally assessed by the treating psychiatrist using several sources of information. Bivariate correlations and mixed model regression analyses were used to test the relationship of insight and medication attitudes to outcomes at baseline and during the follow-up period. Regression models were used to evaluate the relationship between change in insight and medication attitudes and changes outcomes.
RESULTS: There was a significant relationship at baseline between insight and drug attitudes and symptoms of schizophrenia and depression, as well as with community functioning. Higher levels of insight at baseline were significantly associated with lower levels of schizophrenia symptoms at follow-up while more positive medication attitudes were significantly associated with both lower symptom levels and better community functioning. Change in insight scores over time was associated with declining schizophrenia symptoms but increasing levels of depression. Change toward more positive medication attitudes was associated, independently of changes in insight, with significant decreases in psychopathology, improvement in community functioning, and greater medication compliance.
CONCLUSION: Greater patient understanding of their illness and more positive attitudes toward medication may improve outcomes. Educational interventions that affect these attitudes may be an important part of psychosocial rehabilitation and/or recovery-oriented services.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586692      PMCID: PMC2659303          DOI: 10.1093/schbul/sbn067

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  78 in total

Review 1.  Recovery and systems transformation for schizophrenia.

Authors:  Scott A Peebles; P Alex Mabe; Larry Davidson; Larry Fricks; Peter F Buckley; Gareth Fenley
Journal:  Psychiatr Clin North Am       Date:  2007-09

2.  Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression.

Authors:  Kang Sim; Rathi Mahendran; Samuel G Siris; Stephan Heckers; Siow Ann Chong
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

3.  Does insight affect long-term impatient treatment outcome in chronic schizophrenia?

Authors:  R C Schwartz; B N Cohen; A Grubaugh
Journal:  Compr Psychiatry       Date:  1997 Sep-Oct       Impact factor: 3.735

4.  Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

Authors:  G Donohoe; N Owens; C O'Donnell; T Burke; L Moore; A Tobin; E O'Callaghan
Journal:  Eur Psychiatry       Date:  2001-08       Impact factor: 5.361

5.  Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes.

Authors:  Kate Rosen; Philippa Garety
Journal:  Schizophr Bull       Date:  2005-02-16       Impact factor: 9.306

6.  A depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; B Schissel
Journal:  Schizophr Res       Date:  1990 Jul-Aug       Impact factor: 4.939

7.  Awareness of illness in schizophrenia and outpatient treatment adherence.

Authors:  B J Cuffel; J Alford; E P Fischer; R R Owen
Journal:  J Nerv Ment Dis       Date:  1996-11       Impact factor: 2.254

8.  Evaluation of social problem solving in schizophrenia.

Authors:  A S Bellack; M Sayers; K T Mueser; M Bennett
Journal:  J Abnorm Psychol       Date:  1994-05

9.  Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications.

Authors:  Alan S Bellack
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

Review 10.  Identifying mechanisms of treatment effects and recovery in rehabilitation of schizophrenia: longitudinal analytic methods.

Authors:  Jason E Peer; Zeno Kupper; Jeffrey D Long; John S Brekke; William D Spaulding
Journal:  Clin Psychol Rev       Date:  2007-01-18
View more
  63 in total

1.  Social interaction and drug attitude effectiveness in patients with schizophrenia.

Authors:  Jui-Kang Tsai; Wen-Kuo Lin; For-Wey Lung
Journal:  Psychiatr Q       Date:  2011-12

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.

Authors:  Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer
Journal:  BMC Psychiatry       Date:  2018-06-28       Impact factor: 3.630

4.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

5.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

6.  What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Ilja Spellmann; Richard Musil; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

7.  The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia.

Authors:  Yin-Ju Lien; Hsin-An Chang; Yu-Chen Kao; Nian-Sheng Tzeng; Chien-Wen Lu; Ching-Hui Loh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-07-29       Impact factor: 5.270

Review 8.  The effects of aging on insight into illness in schizophrenia: a review.

Authors:  Philip Gerretsen; Eric Plitman; Tarek K Rajji; Ariel Graff-Guerrero
Journal:  Int J Geriatr Psychiatry       Date:  2014-07-23       Impact factor: 3.485

9.  Is personal recovery in schizophrenia predicted by low cognitive insight?

Authors:  Laura Giusti; Donatella Ussorio; Adele Tosone; Chiara Di Venanzio; Valeria Bianchini; Stefano Necozione; Massimo Casacchia; Rita Roncone
Journal:  Community Ment Health J       Date:  2014-07-27

10.  Rehospitalization risk of former voluntary and involuntary patients with schizophrenia.

Authors:  Carmen Pfiffner; Tilman Steinert; Reinhold Kilian; Thomas Becker; Karel Frasch; Gerhard Eschweiler; Gerhard Längle; Daniela Croissant; Wiltrud Schepp; Prisca Weiser; Susanne Jaeger
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-05-08       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.